How does neuroblastoma begin and can we use this knowledge to develop new treatments?
Dissecting the role of MYCN in neuroblastoma initiation
Repurposing antihistamines to reduce treatment-related toxicity for children with WNT-medulloblastoma
Repurposing antihistamines to reduce treatment-related toxicity for children with WNT-medulloblastoma
Exploring a novel drug treatment for osteosarcoma
Drug repurposing targeting immunomodulatory Haem oxygenase-1 (HO-1) for prevention of osteosarcoma growth and metastasis
How does T-cell acute lymphoblastic leukaemia go to the brain?
Identifying drivers of central nervous system involvement in T-cell acute lymphoblastic leukaemia
Advance testing efficacy of albendazole in childhood acute myeloid leukaemia
Investigating the preclinical efficacy of albendazole in paediatric acute myeloid leukaemia
Enhancing immunotherapy for the treatment of paediatric brain tumours
Enhancing CAR T-cell expansion and prolonged persistence for the effective treatment of paediatric medulloblastoma
Developing personalised treatments for brain-directed chemotherapy in childhood acute lymphoblastic leukaemia
ALLTogether1 CSF-FLOW Study
Understanding a potentially new therapeutic target in incurable childhood acute lymphoblastic leukaemia
Dissecting the role of CD133/PROM1 in MLL rearranged acute lymphoblastic leukaemia to develop novel targeted therapy
Understanding treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma
Understanding treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma